Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Movement Disorders : Official Journal of the Movement Disorder Society|May 11, 2006
Restless legs syndrome: epidemiological and clinicogenetic study in a South Tyrolean population isolateFlorian D Vogl, Irene Pichler, Susanna Adel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysisWolfgang Janni, Florian D Vogl, Gro Wiedswang, et al.
Investigational New Drugs|July 8, 2018
A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumorsMichael Carducci, Montaser Shaheen, Ben Markman, et al.
BMC Medical Genetics|June 7, 2007
The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectivesCristian Pattaro, Fabio Marroni, Alice Riegler, et al.
Journal of Clinical Medicine|July 17, 2020
Occult Pathologic Findings in Reduction Mammaplasty in 5781 Patients-An International Multicenter StudyBritta Kuehlmann, Florian D Vogl, Tomas Kempny, et al.
The New England Journal of Medicine|August 27, 2005
A pooled analysis of bone marrow micrometastasis in breast cancerStephan Braun, Florian D Vogl, Bjørn Naume, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2016
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancerChristian Marth, Ignace Vergote, Giovanni Scambia, et al.
Gynecologic Oncology|August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
Cancer Research Communications|September 15, 2023
A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other TumorsGlenn J Hanna, Anastasios Stathis, Elena Lopez-Miranda, et al.
Pageof 2